Figure 4 Figure 5 Meta-regression analysis Meta-regression analyses were performed to assess whether FBG, insulin, HOMA-IR, and HbA1C was affected by L-carnitine doses and intervention durations
Differences in study methodology, coding reliability, follow-up duration and systemic comorbidities continue to complicate interpretation.
Preliminary safety reporting indicated: GI adverse event profile consistent with Phase 2 data No new safety signals identified beyond those observed in earlier trials Discontinuation rates due to adverse events were comparable to other GLP-1 class trials Full adverse event tables from TRIUMPH-4 are expected with the peer-reviewed publication
Using medication beyond the expiration date means the manufacturer can no longer guarantee its potency, purity, or safety
It is the fragmentation of signals across research papers, patents, startup activity, and early product launches